Showing 461 - 480 results of 3,305 for search '"labelling"', query time: 0.06s Refine Results
  1. 461
  2. 462

    Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment by Annabelle M Belcher, Thomas O Cole, Aaron D Greenblatt, Stephen W Hoag, David H Epstein, Michael Wagner, Amy S Billing, Ebonie Massey, Kristen R Hamilton, Zofia K Kozak, Christopher J Welsh, Eric Weintraub, Emerson M Wickwire, Eric D Wish, Ted J Kaptchuk, Luana Colloca

    Published 2019-06-01
    “…Our study combines two promising clinical methodologies—conditioning/dose-extension and open-label placebo—to investigate whether placebo effects can increase the effective potency of methadone in treatment-seeking OUD patients.Methods and analysis A total of 120 newly enrolled treatment-seeking OUD patients will be randomly assigned to one of two different groups: either methadone plus daily placebo dose-extension (PDE; treatment group) or methadone/treatment as usual (control). …”
    Get full text
    Article
  3. 463
  4. 464
  5. 465

    In Vivo Distribution and Therapeutic Efficacy of Radioiodine-Labeled pH-Low Insertion Peptide Variant 3 in a Mouse Model of Breast Cancer by Min Zhang, Yue Xi, Hong Chen, Wangxi Hai, Biao Li

    Published 2022-01-01
    “…This study evaluates the distribution and therapeutic efficacy of radioiodine-labeled pHLIP variant 3 (Var3) in a mouse model of BC. …”
    Get full text
    Article
  6. 466

    Influence of label and academic field on cancer stigma and subjective illness theories among medicine and psychology students: a cross-sectional online study by Mareike Rutenkröger, Sakine Agrali, Isabelle Scholl

    Published 2025-01-01
    “…Medicine students endorsed more stigmatizing statements with the label “cancer survivors,” while psychology students did so with the label “persons with cancer.” …”
    Get full text
    Article
  7. 467
  8. 468

    EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial by Alexander Egeberg, Ditte Georgina Zhang, Christian Vestergaard, Simon Francis Thomsen, Jennifer Astrup Sørensen, Misbah Noshela Ghazanfar, Zarqa Ali, Jacob Thyssen

    Published 2025-01-01
    “…Here, we present the rationale and design of the EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria trial, a multicentre, randomised, open-label, non-inferiority clinical trial. The objective of this trial is to investigate if patients with well-controlled CSU, achieved by standard treatment of 300 mg omalizumab administered subcutaneously every 4 weeks (Q4W) for 12 weeks, can maintain disease control with every 6 weeks (Q6W) dosing interval.Methods and analysis Participants who achieve an Urticaria Control Test (UCT) score ≥12 after 12 weeks on omalizumab will be randomised to 300 mg omalizumab treatment Q4W or Q6W. …”
    Get full text
    Article
  9. 469
  10. 470
  11. 471
  12. 472

    Noninvasive Optical Imaging and In Vivo Cell Tracking of Indocyanine Green Labeled Human Stem Cells Transplanted at Superficial or In-Depth Tissue of SCID Mice by Vikram Sabapathy, Jyothsna Mentam, Paul Mazhuvanchary Jacob, Sanjay Kumar

    Published 2015-01-01
    “…In this study, we have optimized the ICG labelling conditions that is optimal for noninvasive optical imaging and demonstrated that ICG labelled cells can be successfully used for in vivo cell tracking applications in SCID mice injury models.…”
    Get full text
    Article
  13. 473
  14. 474
  15. 475
  16. 476
  17. 477

    Effectiveness of a personal health coaching intervention (diabetescoach) in patients with type 2 diabetes: protocol for an open-label, pragmatic randomised controlled trial by Oliver Faude, Fiona Streckmann, Lukas Zahner, Markus Gerber, Vivien Hohberg, Jan-Niklas Kreppke, Jan Kohl, Eleonora Seelig, Daniel König

    Published 2022-06-01
    “…The intervention will be evaluated in a monocentric, open-label, pragmatic, two-arm randomised controlled trial with a sample ratio of 1:1 and a parallel design. …”
    Get full text
    Article
  18. 478
  19. 479
  20. 480